Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Weber, Martin S ^a,b,c   Prod'homme, Thomas ^a,b   Youssef, Sawsan ^d   Dunn, Shannon E ^d   Steinman, Lawrence ^d   Zamvil, Scott S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BROXURIDINE; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 4; PHOSPHATE BUFFERED SALINE; STAT6 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL KINETICS; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOSTASIS; DISEASE CONTROL; DRUG MECHANISM; DRUG SCREENING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH2 CELL; TREATMENT OUTCOME;

ADENYLATE CYCLASE; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PYRROLES; RATS; STAT6 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TH2 CELLS;

EID: 84896712052     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-29     Document Type: Article

References (51)

1. Goldstein JL, Brown MS. Lipoprotein receptors and the control of plasma LDL cholesterol levels. Eur Heart J 1992, 13(Suppl B):34-36.
2. Youssef S, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84. 10.1038/nature01158, 12422218.
3. Leung BP, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003, 170:1524-1530.
4. Thomas PB, et al. The effects of atorvastatin in experimental autoimmune uveitis. Br J Ophthalmol 2005, 89:275-279. 10.1136/bjo.2004.050401, 1772538, 15722302.
5. Liu W, Li WM, Gao C, Sun NL. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J Autoimmun 2005, 25:258-263. 10.1016/j.jaut.2005.06.005, 16242301.
6. Azuma RW, et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc Res 2004, 64:412-420. 10.1016/j.cardiores.2004.09.014, 15537494.
7. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004, 173:7641-7646.
8. Aktas O, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003, 197:725-733. 10.1084/jem.20021425, 2193848, 12629065.
9. Stanislaus R, Gilg AG, Singh AK, Singh I. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci Lett 2002, 333:167-170. 10.1016/S0304-3940(02)00943-6, 12429374.
10. Greenwood J, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. Faseb J 2003, 17:905-907. 3831156, 12626426.
11. Weber MS, et al. Statins in the treatment of central nervous system autoimmune disease. J Neuroimmunol 2006, 178:140-148. 10.1016/j.jneuroim.2006.06.006, 16860400.
12. Weber MS, Steinman L, Zamvil SS. Statins - treatment option for central nervous system autoimmune disease?. Neurotherapeutics 2007, 4:693-700. 10.1016/j.nurt.2007.08.004, 17920550.
13. Lanzillo R, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 2010, 16:450-454. 10.1177/1352458509358909, 20150398.
14. Togha M, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler 2010, 16:848-854. 10.1177/1352458510369147, 20488825.
15. Sorensen PS, et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 2011, 10:691-701. 10.1016/S1474-4422(11)70144-2, 21742556.
16. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008, 71(18):1390-1395. 10.1212/01.wnl.0000319698.40024.1c, 18525027.
17. Vollmer T, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004, 363:1607-1608. 10.1016/S0140-6736(04)16205-3, 15145635.
18. Waubant E, et al. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology 2012, 78:1171-1178. 10.1212/WNL.0b013e31824f7fdd, 3320055, 22459680.
19. Dunn SE, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006, 203:401-412. 10.1084/jem.20051129, 2118212, 16476765.
20. Rincon M, Flavell RA. Reprogramming transcription during the differentiation of precursor CD4+ T cells into effector Th1 and Th2 cells. Microbes Infect 1999, 1:43-50. 10.1016/S1286-4579(99)80013-6, 10847765.
21. Balamuth F, Leitenberg D, Unternaehrer J, Mellman I, Bottomly K. Distinct patterns of membrane microdomain partitioning in Th1 and th2 cells. Immunity 2001, 15:729-738. 10.1016/S1074-7613(01)00223-0, 11728335.
22. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 2008, 180:6988-6996.
23. Gegg ME, et al. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J Immunol 2005, 174:2327-2335. 3816391, 15699169.
24. Chitnis T, et al. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001, 108:739-747. 10.1172/JCI200112563, 209380, 11544280.
25. Hardardottir F, Baron JL, Janeway CA. T cells with two functional antigen-specific receptors. Proc Natl Acad Sci U S A 1995, 92:354-358. 10.1073/pnas.92.2.354, 42738, 7530361.
26. Mohrs M, Shinkai K, Mohrs K, Locksley RM. Analysis of type 2 immunity in vivo with a bicistronic IL-4 reporter. Immunity 2001, 15:303-311. 10.1016/S1074-7613(01)00186-8, 11520464.
27. Weber MS, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010, 68:369-383. 10.1002/ana.22081, 3375897, 20641064.
28. McDonald F, Mohrs M, Brewer J. Using bicistronic IL-4 reporter mice to identify IL-4 expressing cells following immunisation with aluminium adjuvant. Vaccine 2006, 24:5393-5399. 10.1016/j.vaccine.2006.03.049, 16630673.
29. Weber MS, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007, 13:935-943. 10.1038/nm1620, 17676050.
30. Putheti P, Soderstrom M, Link H, Huang YM. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol 2003, 144:125-131. 10.1016/j.jneuroim.2003.08.001, 14597106.
31. Aharoni R, et al. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J Neuroimmunol 2010, 225:100-111. 10.1016/j.jneuroim.2010.04.022, 20554028.
32. Haas J, et al. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. J Neuroimmunol 2009, 216(1-2):113-117.
33. Nath N, Giri S, Prasad R, Singh AK, Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for multiple sclerosis therapy. J Immunol 2004, 172:1273-1286.
34. Paintlia AS, et al. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J Neurosci Res 2004, 77:63-81. 10.1002/jnr.20130, 15197739.
35. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004, 172:2903-2908.
36. Paul F, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 2008, 3:e1928. 10.1371/journal.pone.0001928, 2276246, 18398457.
37. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A 2005, 102:6449-6454. 10.1073/pnas.0502187102, 1088385, 15851684.
38. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007, 4:647-653. 10.1016/j.nurt.2007.08.002, 17920545.
39. Ke D, Fang J, Fan L, Chen Z, Chen L. Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury. Coron Artery Dis 2013, 24:334-341. 10.1097/MCA.0b013e3283608c12, 23531479.
40. Hu Z, Li D, Hu Y, Yang K. Changes of CD4+CD25+ regulatory T cells in patients with acute coronary syndrome and the effects of atorvastatin. J Huazhong Univ Sci Technol Med Sci 2007, 27:524-527. 10.1007/s11596-007-0512-4, 18060626.
41. Mausner-Fainberg K, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008, 197:829-839. 10.1016/j.atherosclerosis.2007.07.031, 17826781.
42. Weber MS, Zamvil SS. Statins and demyelination. Curr Top Microbiol Immunol 2008, 318:313-324.
43. Weber MS, Prod'homme T, Steinman L, Zamvil SS. Drug insight: using statins to treat neuroinflammatory disease. Nat Clin Pract Neurol 2005, 1:106-112. 10.1038/ncpneuro0047, 16932506.
44. Chataway J, MacManus AA, Chan D, Hunter K, Foster J, Bangham C, Wilkie D, Nicholas J, Clegg S, Nielsen C, Scheurer N, Calder V, Greenwood J, Frost C, Nicholas R. The MS-STAT Trial: high dose simvastatin demonstrates neuroprotection without immune-modulation in secondary progressive multiple sclerosis (SPMS) - a phase II trial [Abstract]. 2012, 11-13. Lyon, France, Presented at European Committee for Treatment and Research in Multiple Sclerosis.
45. Sellner J, et al. The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?. CNS Neurosci Ther 2010, 16:362-373. 10.1111/j.1755-5949.2010.00179.x, 20626428.
46. Costello F, Stuve O, Weber MS, Zamvil SS, Frohman E. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr Opin Neurol 2007, 20:281-285. 10.1097/WCO.0b013e328122de1b, 17495621.
47. Stuve O, et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006, 116:1037-1044. 10.1172/JCI25805, 1401481, 16543951.
48. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995, 270:29682-29689. 10.1074/jbc.270.50.29682, 8530356.
49. Bruck W, et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol 2013, doi: 10.1001/jamaneurol.2013.3510. [Epub ahead of print].
50. Linker RA, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain J Neurol 2011, 134:678-692.
51. Lehmann JC, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 2007, 127:835-845. 10.1038/sj.jid.5700686, 17235328.